Related Experiment Video
Updated: May 13, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin
C H Y Chan1, R D Hansen, R S Gilliver
1Department of Gastroenterology and Hepatology, Royal North Shore Hospital, Sydney, Australia.
Background:
Insulin resistance (IR) is a key factor in the development of hepatic steatosis and fibrosis in chronic hepatitis C virus infection. Little is known about the impact of viral clearance on IR.
Aim:
The aim of this study was to determine the impact of viral clearance on IR.
Methods:
Eighty-six patients treated according to standard clinical practice at an Australian teaching hospital between 2003 and 2007 were prospectively studied. Demographic, biochemical and histological data were collected.
Results:
The mean pretreatment homeostatic model assessment-IR (HOMA-IR) was similar in the sustained virological response (SVR) and non-SVR groups (2.7 ± 0.5 and 2.8 ± 0.4, respectively), and both values were consistent with significant IR. There was a significant improvement in HOMA-IR (from 3.0 ± 1.0 to 2.2 ± 0.5, P = 0.04) at the end of treatment in the SVR group only. This trended towards significance at 6 months post-treatment. Multiple regression analysis found improvement in both gamma-glutamyl transpeptidase and alanine aminotransferase predicted improvement in HOMA-IR when controlled for other potential factors (P = 0.01).
Conclusions:
Hepatitis C virus clearance is associated with improvement in IR. Although baseline hepatic fibrosis is a predictor of IR, changes in IR appear to be independent of changes in liver fibrosis. Treatment-related improvement in gamma-glutamyl transpeptidase and alanine aminotransferase seen with improved IR may be a possible marker of reduction of hepatic oxidative stress.
More Related Videos
Related Concept Videos
Hepatitis
Type II Diabetes II: Pathophysiology
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
Type I Diabetes II: Pathophysiology
Inhibitors of Viral Protein Synthesis

